Table 1.
Patient demographic and pancreatic mass characteristics
| Variables | Patients (n = 30) |
|---|---|
| Age, mean ± SD, (y) | 65.2 ± 9.2 |
| Men, no. (%) | 16 (53.3%) |
| Location of mass, no. (%) | |
| Head or neck | 14 (46.7%) |
| Body or tail | 16 (53.3%) |
| Size of mass on EUS, (mm) | |
| Mean ± SD | 34.6 (12.3) |
| Median | 32 |
| <20 mm, n | 2 (6.7%) |
| ≥20 mm, n | 28 (93.3%) |
| Final diagnosis, no. (%) | |
| Malignancy | |
| Pancreatic ductal adenocarcinomaa | 24 (80.0%) |
| Neuroendocrine carcinoma | 1 (3.3%) |
| Metastatic cancerb | 2 (6.7%) |
| Benign disease | |
| IgG4‐related disease | 1 (3.3%) |
| Autoimmune pancreatitis | 1 (3.3%) |
| Chronic pancreatitis | 1 (3.3%) |
Abbreviation: EUS, Endoscopic ultrasound.
a
Two patients were diagnosed with pancreatic adenocarcinoma in the second study‐free EUS‐FNB and open pancreatic biopsy.
b
Metastatic cancer originated from lung cancer and Klatskin tumor.